F2G Limited Appoints Francesco Maria Lavino as CEO and Member of the Board

• F2G Limited announced that Francesco Maria Lavino has been appointed Chief Executive Officer (CEO) and member of the Board of F2G. Maria brings substantial specialty pharmaceutical leadership and expertise in the antifungal arena. Prior she has served as AVP, Global Brand Leader, Anti-infectives portfolio at Merck & Co., and as Chief Commercial Officer of Nabriva Therapeutics Inc.

• Ian Nicholson is stepping down as CEO following eight years of dedicated service to F2G to pursue non-executive roles and will provide support to ensure an effective transition. 

F2G Limited is a Biotech company based in the UK and Australia. Its focus is to discover and develop therapies to treat fungal infections.